Telix today announces additional positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Identifier: NCT03849118).

Telix today announces presentations from the Company’s carbonic anhydrase IX (CAIX) targeting kidney and bladder cancer programs at the 38th Annual European Association of Urology (EAU) Congress to be held in Milan from 10 – 13 March 2023.

Telix is pleased to provide a webcast recording of A/Prof Brian Shuch and Dr Colin Hayward, Telix Group Chief Medical Officer. The briefing provided an opportunity for investors to hear Dr Shuch’s ASCO-GU presentation and a clinician’s perspective on the clinical utility of this investigational imaging agent.

ASCO GU (February 16-18, 2023), the leading specialised event for GU cancer care worldwide, will be the forum at which the Company will present results of the Phase III ZIRCON study (ClinicalTrials.gov Identifier: NCT03849118) of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC). The program will also include six presentations on Telix’s carbonic anhydrase IX (CAIX)- and prostate specific membrane antigen (PSMA)-targeting theranostic candidates. Presentations will report on advancements in positron emission tomography (PET) imaging of prostate cancer with 68Ga PSMA-11; the potential utility of TLX250-CDx in tumour types beyond ccRCC; and the STARLITE Phase II studies, which are assessing the efficacy of TLX250 (177Lu-DOTA-girentuximab) targeted radiation in combination with immunotherapy for ccRCC.

Telix is pleased to provide a webcast recording of CEO and MD Dr. Christian Behrenbruch presenting at the J.P. Morgan Healthcare Conference on Wednesday 11 January 2023.

Telix is pleased to present a webcast of CEO and MD Dr. Christian Behrenbruch presenting at the Jefferies London Healthcare Conference in London on Thursday 17 November 2022.

At our recent EANM 2022 symposium, Telix brought together some of the world’s key opinion leaders to discuss the impact that nuclear medicine is having on their field. It was an exciting and informative afternoon filled with fascinating insights. If you missed the event, you can find interesting aspects from each of our expert speakers below. Prepare to shift your perspectives!

We are pleased to announce that Telix is supporting AdMeTech Foundation’s 6th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer, to be held virtually from September 22-24 2022.

We are pleased to announce that Telix will be hosting a Luncheon Seminar at the 13th Congress of the World Federation of Nuclear Medicine and Biology (WFNMB), to be held at the Kyoto International Conference Center from September 7-11 2022.